| Nada Lygrisse, DO | |
|
102 W Kenwood Ave, Decatur, IL 62526-4368 | |
| (217) 545-8000 | |
| Not Available |
| Full Name | Nada Lygrisse |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 10 Years |
| Location | 102 W Kenwood Ave, Decatur, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871919134 | NPI | - | NPPES |
| 0316886 | Medicaid | OH |
| Facility Name | Location | Facility Type |
|---|---|---|
| Decatur Memorial Hospital | Decatur, IL | Hospital |
| St Marys Hospital | Decatur, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lake Shore Ob Gyn Of Decatur Sc | 1658269840 | 2 |
News Archive
Each year, millions of people designate January 1 as the day they are going to make a change. Stop smoking. Save money. Exercise regularly. Whatever the pledge, countless Americans try—and frequently fail—to make changes in their lives. Most start strong, but by February have all but abandoned their newfound goals.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
Today's headlines include various stories about the health law's implementation at both the federal and state level.
The Myelodysplastic Syndromes Group of Josep Carreras Leukaemia Research Institute, led by Dr. Francesc Solé, has participated in the first international study that confirms that having two mutated copies of the TP53 gene, as opposed to a single mutated copy, is associated with a worse prognosis in patients diagnosed with myelodysplastic syndrome (MDS).
› Verified 9 days ago
| Entity Name | Methodist Medical Center Of Illinois |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982656575 PECOS PAC ID: 1355259714 Enrollment ID: O20031126000494 |
News Archive
Each year, millions of people designate January 1 as the day they are going to make a change. Stop smoking. Save money. Exercise regularly. Whatever the pledge, countless Americans try—and frequently fail—to make changes in their lives. Most start strong, but by February have all but abandoned their newfound goals.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
Today's headlines include various stories about the health law's implementation at both the federal and state level.
The Myelodysplastic Syndromes Group of Josep Carreras Leukaemia Research Institute, led by Dr. Francesc Solé, has participated in the first international study that confirms that having two mutated copies of the TP53 gene, as opposed to a single mutated copy, is associated with a worse prognosis in patients diagnosed with myelodysplastic syndrome (MDS).
› Verified 9 days ago
| Entity Name | Lake Shore Ob Gyn Of Decatur Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700925583 PECOS PAC ID: 1658269840 Enrollment ID: O20040309000715 |
News Archive
Each year, millions of people designate January 1 as the day they are going to make a change. Stop smoking. Save money. Exercise regularly. Whatever the pledge, countless Americans try—and frequently fail—to make changes in their lives. Most start strong, but by February have all but abandoned their newfound goals.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
Today's headlines include various stories about the health law's implementation at both the federal and state level.
The Myelodysplastic Syndromes Group of Josep Carreras Leukaemia Research Institute, led by Dr. Francesc Solé, has participated in the first international study that confirms that having two mutated copies of the TP53 gene, as opposed to a single mutated copy, is associated with a worse prognosis in patients diagnosed with myelodysplastic syndrome (MDS).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nada Lygrisse, DO 201 E Madison St Ste 303, Springfield, IL 62702-5131 Ph: (217) 545-3787 | Nada Lygrisse, DO 102 W Kenwood Ave, Decatur, IL 62526-4368 Ph: (217) 545-8000 |
News Archive
Each year, millions of people designate January 1 as the day they are going to make a change. Stop smoking. Save money. Exercise regularly. Whatever the pledge, countless Americans try—and frequently fail—to make changes in their lives. Most start strong, but by February have all but abandoned their newfound goals.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
Today's headlines include various stories about the health law's implementation at both the federal and state level.
The Myelodysplastic Syndromes Group of Josep Carreras Leukaemia Research Institute, led by Dr. Francesc Solé, has participated in the first international study that confirms that having two mutated copies of the TP53 gene, as opposed to a single mutated copy, is associated with a worse prognosis in patients diagnosed with myelodysplastic syndrome (MDS).
› Verified 9 days ago
Dr. Gretchen L Byrkit, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: One Memorial Dr, Ste 216, Decatur, IL 62526 Phone: 217-875-5574 Fax: 217-875-5724 | |
Jeffrey Pfeiffer, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 544 West Pershing Road, Suite A, Decatur, IL 62526 Phone: 217-872-2400 | |
Vidya Sagar Rao Morisetty, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 675 E Snyder Dr Ste 1, Decatur, IL 62526 Phone: 217-875-1886 Fax: 217-875-3120 | |
Roy Tsuda, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: One Memorial Drive, Suite 300, Decatur, IL 62526 Phone: 217-875-5565 Fax: 217-875-4680 | |
Trevor D. Lineberry, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: One Memorial Drive, Suite 300, Decatur, IL 62526 Phone: 217-875-5545 Fax: 217-875-4680 | |
Dr. Douglas Venice Combs, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 320 E Central Ave, Decatur, IL 62521 Phone: 217-545-8000 | |
Pierre Michael Johnson, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1 Memorial Dr, Suite 300, Decatur, IL 62526 Phone: 217-872-2400 Fax: 217-875-4680 |